This content is from: Premium Hedge Funds Are Holding Their Breath on This Biopharma IPO Several prominent hedge funds disclosed sizable stakes in PepGen, which went public earlier this month. By Stephen Taub May 23, 2022
This content is from: Portfolio Why Investors Should Say No to Tech IPOs In the last decade, late-stage investments made before companies go public have generated the highest alpha. By Hannah Zhang May 10, 2022
This content is from: Portfolio With the Pullback in IPOs, Shareholders in Private Companies Are Selling — And Prices Are Dropping With the rise of Forge and other platforms, employees, hedge funds, and other investors are getting liquidity even though the window to go public has closed. By Hannah Zhang April 21, 2022
This content is from: Portfolio SPACs Are Sputtering. Desperate New Terms Could Send Them Into a Death Spiral. Bankers, lawyers, and sponsors all said, “It’s different this time.” But it wasn’t. By Michelle Celarier May 16, 2022
This content is from: Premium Hedge Funds Gear Up for a Rare IPO AN2 Therapeutics hopes to buck the recent trend for new issues. By Stephen Taub March 22, 2022
This content is from: Premium Newly Public Companies Show Some Life Many recent IPOs have rebounded sharply from their lows but still remain well below the prices at which they went public. By Stephen Taub March 29, 2022
